https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50456 2 cm (4.5%) or grade 3 tumors (5.5%). These sustained reductions of the risk of recurrence with adjuvant exemestane + OFS, compared with tamoxifen + OFS, provide guidance for selecting patients for whom exemestane should be preferred over tamoxifen in the setting of OFS.]]> Wed 28 Feb 2024 15:10:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16287 Wed 11 Apr 2018 11:53:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32778 Wed 07 Feb 2024 16:54:46 AEDT ]]>